Bone metabolic markers, TRAP, and Zometa's effect on bone metastasis due to lung cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Cancer metastases; Liver cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Apr 2011 Planned end date changed from 1 Dec 2008 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 14 Apr 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.